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Strengths and limitations of the study
 ► The flexible exercise participation programme 
(FEPP) is a consumer- driven programme for individ-
uals with multiple sclerosis.
 ► Consumer preference for sport or exercise mode is 
central to the FEPP.
 ► Active participation in exercise or sport is focused on 
participation rather than impairment.
 ► Study findings will inform the design of a larger trial.
 ► This study without a control group demonstrates 
feasibility rather than efficacy.
AbStrACt
Introduction Individuals with minimal disability from 
multiple sclerosis (MS) requested advice on finding the 
right balance, between too much and too little exercise, 
when participating in their choice of sport or exercise. To 
optimise exercise participation during the early stages of 
the disease, a flexible exercise participation programme 
(FEPP) has been developed. The FEPP is novel because 
it provides guidance and support for individuals with 
MS to participate and progress in their preferred sport 
or exercise. The primary objective was to assess the 
feasibility of the FEPP. The secondary objective was to 
assess the feasibility of a larger trial to demonstrate the 
efficacy of the FEPP.
Methods and analysis A stage I feasibility study of 
the FEPP, using a single group preintervention/post- 
intervention design, will be conducted with 16 participants 
with minimal disability from MS (Expanded Disability 
Status Scale level of 0–3.5). The 12- week FEPP will 
guide participants to independently participate in their 
preferred sport or exercise at a location of their choice. 
Exercise progression will be guided by individual energy 
levels and a weekly telephone coaching session with 
a physiotherapist. Participation in exercise or sport will 
be recorded in parallel with assessment of disease 
biomarkers (plasma cytokines interleukin (IL)-2, IL-4, IL-6, 
IL-10, interferon (IFN)-γ and tumour necrosis factor (TNF)), 
subjective vitality and high- level mobility. Acceptability of 
the FEPP will be assessed using a sequential explanatory 
mixed methods design where the findings of a participant 
survey will inform the interview guide for a series of focus 
groups.
Feasibility of a larger trial will be assessed via process, 
resources, management and scientific metrics. 
Progression to a larger trial will depend on the 
achievement of specified minimum success criteria.
Ethics and dissemination Ethical approval has 
been obtained for this study from the James Cook 
University Human Research Ethics Committee (H7956). 
Dissemination of findings is planned via peer- reviewed 
journals, conference presentations and media releases. 
The protocol date was 21 December 2019, V.1.
trial registration number The trial is registered with 
Australian New Zealand Clinical Trials Registry (ANZCTR), 
ACTRN12620000076976.
IntroduCtIon
Individuals with minimal disability from 
multiple sclerosis (MS), have recently 
reported participating in, or wanting to 
participate in, sport or high- level exercise, 
such as running, squash or road cycling.1 
While their preference was to undertake 
their choice of sport/exercise independently 
at a time suitable to them, they also wanted 
advice on finding the correct balance 
between too much activity, which may exac-
erbate symptoms, and too little activity, which 
could unnecessarily limit participation. Yet 
few study participants had received any such 
advice, nor had they been given their choice 
of exercise.1 Commonly, exercise interven-
tions for individuals with MS are provided in a 
clinical or home- based setting where the indi-
vidual follows a prescribed activity or exercise 
programme. High- level mobility activities 
such as running, sport or outdoor leisure 
pursuits are not typically targeted.2 Instead, 
exercise interventions prescribed include 
progressive resistance training, balance 
training and stationary cycling, addressing 
impairments such as strength and balance.3–5 
Functional outcomes are typically focused on 
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high- level mobility, even for those who are higher func-
tioning.2 Benefits of participation in regular sport and 
exercise according to the preference of individuals with 
MS have not been reported.
Empowering individuals with the autonomy to manage 
their own exercise prescription, according to their indi-
vidual goals, is an important concept in exerting control 
over the impact of the disease. Previous interventions 
examined in clinical trials for MS have not commonly 
allowed for this diversity. Therefore, exploration of 
ways to adapt and modify personal exercise choices to 
improve or maintain participation is required. To address 
this need, a flexible exercise participation programme 
(FEPP) has been developed to offer individuals choice 
and to guide their mode and dose of exercise. The 
FEPP has been based on existing recommendations for 
general and advanced aerobic exercise for individuals 
with MS.8 It has also been informed by the guidelines for 
healthy individuals proposed by the American College of 
Sports Medicine and equivalent version by the Australian 
Government Department of Health, which aim to reduce 
the risk of chronic disease.9 10 The FEPP is a stepping stone 
supported pathway to move from low levels of aerobic 
exercise towards meeting or exceeding advanced aerobic 
exercise guidelines for individuals with MS. The aim of 
the FEPP is to assist individuals with minimal disability 
from MS in finding the right balance between too little 
and too much exercise, and to maximise the benefits of 
exercise for individuals with MS. The FEPP provides a 
personally tailored programme to achieve exercise partic-
ipation goals specific to the individual and is guided by 
the individual’s perceived energy levels. By monitoring 
and responding to energy levels, participants are using 
a pacing technique, which is a method for managing 
energy effectively,11 thereby enabling participation. The 
FEPP provides a framework for a graded response to exer-
cise rather than an ‘all- or- nothing’ approach. Support is 
provided on a weekly basis, by a physiotherapist, using 
recognised behaviour change techniques to enable indi-
viduals to vary their physical activity.12 It is evident that 
individuals with MS need support to increase and maxi-
mise participation in their choice of exercise.1
Many individuals with mild to moderate disability from 
MS do not meet recommended levels of physical activity 
required to obtain fitness benefits13 despite guideline 
recommendations.8 14 For those who do, the guidelines 
provide a baseline for exercise,8 but the maximum safe 
dose is not yet known.14 Manipulation of the exercise dose 
is required to determine the optimum level, which maxi-
mises benefits and is free from negative consequences, 
for each individual with MS. Historically, concerns existed 
around the possibility of exercise increasing fatigue for 
individuals with MS.15 Even though evidence now suggests 
otherwise,16 levels of fatigue continue to guide practice.14 
In the FEPP, a shift away from such impairment- based 
assessment is proposed with assessment of perceived 
energy levels prior to exercise to guide selection of exer-
cise dose. Energy conservation approaches for individuals 
with MS are important tools for planning and pacing 
activities in order to manage fatigue in daily life.11 17 
Attention to available energy prior to exercise may enable 
an informed decision on whether to progress, maintain 
or regress exercise dose, and assist in finding the right 
balance between too much and too little activity. Measure-
ment of vitality following a period of regular participation 
in exercise may also serve to demonstrate long- term bene-
fits of exercise.18
Physiological benefits of exercise include improvements 
in aerobic capacity, balance and muscle strength.19–21 
In addition, it has been proposed that exercise may 
have a neuroprotective and disease- modifying effect 
on MS.22 23 Biomarkers that may serve as indicators of 
exercise- induced neural changes in MS include neuro-
trophic factors and cytokines.24 Neurotrophic factors 
can increase as a result of exercise, such as brain- derived 
neurotrophic factor, which has a role in neurogenesis and 
neuroprotection of the central nervous system.22 25 Cyto-
kine levels have also shown change following exercise in 
individuals with MS.26 27 Cytokines assist in regulating the 
immune response.28 In MS, there is an imbalance between 
the levels of proinflammatory and anti- inflammatory 
cytokines, with higher levels of proinflammatory cyto-
kines linked to the demyelination process.28 Reduction 
in proinflammatory cytokines can occur following exer-
cise.26 However, the evidence is inconsistent as to whether 
the change in cytokine profile is the mechanism for 
physiological improvement following exercise and hence 
requires further investigation.29 Furthermore, the effects 
of exercise dose (ie, frequency, intensity, duration and 
mode) on cytokine levels remains unknown.29 30
The purpose of this study was to assess the feasibility 
of the FEPP, a novel sport and exercise intervention for 
individuals with MS. Individuals with minimal disability 
from MS will be invited to participate in their preferred 
exercise. Response to exercise dose will be assessed using 
disease biomarkers, subjective vitality, as a measure of 
energy, high- level mobility, and subjective reporting. The 
objectives of the study were to
1. Assess the feasibility of the FEPP for individuals with 
minimal disability from MS.
a. Does the FEPP enable achievement of goals for par-
ticipation in exercise and sport for individuals with 
MS?
b. What is the best method to describe and report on 
the exercise or sport intervention?
c. Is there a relationship between the level of partic-
ipation in exercise and clinical/physiological out-
comes?
 – Plasma cytokine levels (IL-2, IL-4, IL-6, IL-10, 
IFN-γ and TNF).
 – Vitality (energy levels measured via the Subjective 
Vitality Scale).
 – High- level mobility (measured via the High- Level 
Mobility Assessment Tool (HiMAT)).
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2. Assess the feasibility of a larger clinical trial against the 
following minimum success criteria:
a. No reports of serious adverse events as a result of 
completing the FEPP.
b. A minimum of 80% of participants able to modify 
exercise participation using the FEPP.
c. A minimum of 80% of participants report satisfac-
tion with the FEPP.
d. A minimum of 20% attrition from the 12- week FEPP.
e. A minimum of 75% recruitment of the intended 16 
participants.




This stage I feasibility study will involve a single group 
preintervention/post- intervention design to explore 
implementation of a 12- week FEPP with individuals with 
minimal disability from MS. Participation in exercise 
or sport will be recorded in parallel with assessment of 
disease biomarkers, subjective vitality and high- level 
mobility.
Acceptability of the FEPP to participants will be 
assessed using a sequential explanatory mixed methods 
design.31 Perceived effective/ineffective elements of the 
FEPP and potential adaptations will be explored to guide 
refinement of the FEPP. Assessment of feasibility metrics 
(process, resources, management and scientific) will 
inform the suitability of a larger trial.
Study setting
Data collection will occur in the James Cook University 
(JCU), Australia, in January 2020. The intervention will 
occur according to each participant’s preferred mode of 
exercise and preferred setting, for example, sports centre, 
gym or outdoor pursuit in his/her local environment.
Participants
Individuals with MS who meet the following inclusion 
criteria will be invited to participate: (1) diagnosis of 
relapsing remitting MS as defined by the 2017 McDonald 
criteria32; (2) independent mobility as defined by 
Expanded Disability Status Scale level 0–3.533; (3) stability, 
that is, not worsening in the past 3 months on disease- 
modifying drugs (e.g. alemtuzamab, natalizumab and 
ocrelizumab)34; (4) 18 years of age or over; and (5) ability 
to provide informed consent. Potential participants will 
be excluded if they have (1) any concomitant neurolog-
ical condition or (2) an additional health condition that 
would prohibit their participation in aerobic exercise or 
sport.
recruitment
Participants will be recruited via (1) media: television, 
newspaper and social media; (2) flyer distributed by MS 
Queensland and by consultant neurologists; (3) flyer 
displayed in community settings (eg, community notice 
boards and medical practices; (4) JCU website and social 
media; and (v) snowballing. Potential participants will 
be advised to contact the primary researcher by email or 
telephone for further information. Once contacted, the 
primary researcher will screen potential participants in 
person or via telephone against the inclusion/exclusion 
criteria.
All potential participants who meet the eligibility 
criteria will be provided with an information letter and a 
consent form, either electronically or via post with a reply- 
paid envelope, according to their preference. Those who 
wish to participate will be advised to return the signed 
consent form in person, electronically or via post. Partic-
ipants can withdraw from the study at any time without 
explanation or prejudice.
Sample size
Sixteen participants will be recruited, allowing for a 25% 
dropout rate. A sample size of 12 participants has been 
recommended for feasibility studies.35 As this study is 
designed to assess the feasibility of a larger trial, a formal 
sample size calculation will not be required.
Intervention
All 16 participants will undertake the FEPP, a 12- week 
programme, in which participants choose their preferred 
mode of exercise as well as the time and location for 
exercise. Exercise will be performed independently by 
the participant (ie, not supervised by the research team). 
The FEPP is illustrated in flowchart format in figures 1 
and 2. The FEPP flowchart will guide the participant to 
incrementally progress, maintain or regress their activity 
level based on performance feedback. The FEPP has two 
streams (table 1) to enable progression of activity level 
relative to the individual’s baseline activity level.
Stream 1 is for participants who do not meet the MS 
general aerobic exercise guidelines of at least 30 min 
of moderate intensity aerobic exercise three times per 
week.8 Moderate intensity exercise is defined as 40%–59% 
of heart rate reserve and can be scored as 12–13 on a 
6–20 rating of perceived exertion (RPE) scale.9 Partici-
pants progress through the stream modifying frequency 
and duration of exercise, as guided by the FEPP, until 
they reach the MS general aerobic exercise guidelines.8 
Participants can opt to maintain this activity level for the 
remainder of the programme if they are satisfied with 
their participation in their chosen sport or exercise in 
accordance with their goals. Alternatively, participants 
can progress through stream 2.
Stream 2 is for participants who meet MS general 
aerobic exercise guidelines. This stream is designed 
to incrementally progress exercise towards meeting or 
exceeding the MS advanced aerobic exercise guide-
lines.8 These guidelines recommend an exercise duration 
approaching 40 min; frequency approaching 5 days per 
week and intensity approaching 15 on an RPE scale of 
6–20 points.8 Participants progress through the stream by 
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Figure 1 FEPP stream 1.
Figure 2 FEPP stream 2.
until they are satisfied with their participation in their 
chosen sport or exercise in accordance with their goals. 
This may be below, at or above MS advanced aerobic exer-
cise guidelines. Participants continue with their optimum 
participation for the duration of the programme.
Each participant will begin the FEPP with an individual 
interview conducted by a physiotherapist (MS) to identify 
and discuss their goals for participation in sport or exercise. 
The participant determines their mode of exercise or sport, 
whether performed individually, with others or as part of 
a team, and indoors or outdoors. This information will be 
recorded in the participant database and exercise diary. 
Exercise progression will be guided by the FEPP. The FEPP 
stream allocation will be determined by the participant’s 
baseline activity level recorded on entry to the programme.
Progression through the FEPP for both streams will be 
determined by the participant’s rating of perceived energy 
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Figure 3 Energy Monitoring Tool.
Table 1 FEPP streams
Current aerobic exercise Intervention Outcome
Stream 1
Does not meet MS general 
aerobic exercise guidelines
Less than 30 min moderate 
intensity three times per week
FEPP stream 1 MS general aerobic exercise guidelines are 
achieved, with progress to stream 2.
Stream 2
Meets MS general aerobic 
exercise guidelines
30 min or more of moderate 
intensity three times per week
FEPP stream 2 Exercise participation goals are satisfied, 
which may be below, at or above MS 
advanced aerobic exercise guidelines.
FEPP, flexible exercise participation programme; MS, multiple sclerosis.
would you rate your overall energy levels this week?’, will be 
scored by participants using the Energy Monitoring Tool, 
a 5- point energy Likert scale ranging from no energy to 
maximum energy (figure 3). Single- item questions such 
as this are used commonly to provide a quick response 
to self- rated health status.36 The Energy Monitoring Tool 
will guide incremental progressions or regressions using 
manipulation of frequency, intensity, time and type of exer-
cise, that is, the FITT principle of exercise prescription,9 as 
indicated on the FEPP (figures 1 and 2).
Prior to and throughout the 12- week period, partici-
pants will be supported to participate in exercise or sport 
via a coaching session with a physiotherapist, once each 
week, via telephone. Behaviour change techniques known 
to assist with participation in exercise and sport12 will be 
used as listed in table 2, together with their definition12 
and planned application.
outcome measures and data collection
Data collection will take place via face- to- face visits, tele-
phone interviews, email or post. Outcome measurement 
will occur face- to- face at JCU, Australia. The timeline for 
data collection of each outcome measure is displayed in 
table 3.
Feasibility outcomes
The primary objective of the study was to assess the feasi-
bility of implementing the FEPP for individuals with MS, 
in accordance with stage I feasibility trials specific to MS.37 
Process, resources, management and scientific feasibility 
outcomes will be assessed. Process measures will include 
participant recruitment, eligibility, refusals, retention and 
attrition. Resources and management refer to the admin-
istrative aspects of the study such as data entry, finance and 
communication time with participants and staff. Scien-
tific feasibility outcomes address aspects of safety, adverse 
events, compliance and potential treatment effects. This 
process of recording feasibility metrics has been used in 
other feasibility studies with MS populations.38 39
Clinical outcomes
Clinical outcomes will include the three domains of the 
International Classification of Functioning, Disability and 
Health framework,40 which are body structures/func-
tions, activities and participation.
Primary outcome
Participation
The primary clinical outcome is participation goals in 
sport and exercise according to the participant’s choice 
measured by the Goal Attainment Scale (GAS).41 42 The 
GAS measures goal achievement (positive or negative) on 
a 5- point scale and can be quantified as a single aggre-
gated goal attainment score for analysis.42 The GAS is a 
responsive measure for individuals with MS.43
During the preintervention interview with the primary 
researcher, participants will be asked to identify their 
goals for participation in exercise and sport. The partic-
ipant will be guided to set specific, measurable, achiev-
able, relevant and timed (SMART) goals,44 for example, 
to cycle to work three times per week by the final 2 weeks 
of the FEPP. One to three goals will be set to represent the 
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Table 2 Behaviour change techniques, definitions and application framework
Technique Taxonomy definition (brief) Application framework
Goal setting (outcome) The person is encouraged to set a goal that can be achieved 
by behavioural means but is not defined in terms of behaviour.
Exercise and sport participation goals will be 
set by the participant following consultation 
with the physiotherapist.
Session: initial interview.
Action planning Involves detailed planning of what the person will do, 
including, as a minimum, when, in which situation and/or 
where to act. ‘When’ may describe frequency or duration.
Guidance on the application of the FEPP to 
ensure appropriate and correct usage.
Session: initial interview and weekly coaching.
Barrier identification/
problem solving
The person is prompted to think about potential barriers and 
to identify the ways of overcoming them. Barriers may include 
competing goals in specified situations. This may be described 
as ‘problem solving’. Examples of barriers may include 
behavioural, cognitive, emotional, environmental, social and/or 
physical barriers.
Discussion of barriers to participating in 
sport and exercise and potential ways of 
overcoming them.
Session: weekly coaching.
Prompt review of 
outcome goals
Involves a review or analysis of the extent to which previously 
set outcome goals were achieved.
Discussion of progress towards participation 
goals.
Session: weekly coaching.
Prompt self- monitoring 
of behaviour
The person is asked to keep a record of specified measures 
expected to be influenced by the behaviour change, for 
example, blood pressure, blood glucose, weight loss and 
physical fitness.
Completion and submission of exercise diary 
each week.
Session: weekly coaching.
Provide feedback on 
performance
This involves providing the participant with data about their 
own recorded behaviour.
Discussion and feedback on activity recorded 
in exercise diary.
Session: weekly coaching.
FEPP, Flexible exercise participation programme.
participant will take place during the postintervention 
interview with the primary researcher.
Secondary outcomes
Body structures and function: plasma cytokines
To identify the effects of exercise on cytokines, a 4 mL 
blood sample will be collected from each participant via 
pathology services during the week preintervention and 
postintervention, which is in accordance with similar 
studies.26 27 45 Blood samples will be collected between 
08:00 and 09:30, following an overnight fast of at least 
10 hours. Samples will be collected in the morning to 
prevent any circadian changes in gene expression and 
to allow for a more meaningful comparison.46 Blood will 
be collected in 4 mL EDTA vacutainers. Following collec-
tion, blood samples will be chilled and immediately trans-
ferred to the JCU Molecular and Cell Biology Department 
for processing. The samples will be centrifuged, plasma 
collected and stored at −80°C until all samples are ready 
for analysis. Cytokine levels (IL-2, IL-4, IL-6, IL-10, IFN-γ 
and TNF) will then be tested, following manufacturer’s 
instructions, using the commercially available kit: BD 
Cytometric Bead Array (CBA) Hu Th1/Th2 Cytokine Kit 
II.
Body functions: vitality
Perceptions of vitality will be self- reported by partici-
pants using the six- item version of the Subjective Vitality 
Scale, which has been validated for use with the general 
population47 and has previously been used with the MS 
population.48 The Subjective Vitality Scale assesses the 
experience of being full of energy and alive, via six ques-
tions rated on a 7- point scale from ‘not at all true’ to 
‘very true’, and provides an overall score of participants’ 
energy.47 The primary researcher will collect these data 
at four time periods across the study: baseline and 4, 8 
and 12 weeks (completion) via face- to- face or telephone 
interview.
Activities: high-level mobility
High- level mobility (ie, running or jumping) will be 
measured using the HiMAT49 to explore the relationship 
between high- level mobility and participation in exercise 
for individuals with MS. The HiMAT assesses high- level 
mobility across 13 items, such as running, jumping and 
climbing stairs, with a total point score of 54 and higher 
scores indicating higher levels of mobility. The HiMAT is 
a valid and reliable tool for assessing high- level mobility.50 
A physiotherapist, who is independent of the interven-
tion that has been trained in the use of the HiMAT, will 
assess the participants during the 1- week preintervention 
and postintervention period.
Participation
Participation in sport or exercise during the interven-
tion period will be measured using an exercise diary. The 
participant will record the frequency, intensity, time and 
type of exercise undertaken each week in an electronic 
exercise diary and email it to the primary researcher on 
a weekly basis. Where participants do not have access to 
email, a paper format will be provided, together with a 
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Table 3 Data collection and outcome measures















 ► All contacts with potential participants.
 ► Participant flow through study.








  Resources  ► Communication.
 ► Finance.
Documentation of
 ► Duration and frequency of 
communication between participants/
staff (email, telephone and face- to- face 
contact).
 ► Communication difficulties.








  Management  ► Data management.
 ► Staff management.
Documentation of
 ► Data collection times.
 ► Data entry and checking of data.








  Scientific  ► Safety.
 ► Adverse events.
 ► Compliance.
 ► Treatment effect.
Documentation of adverse and serious 
adverse events
 ► Via exercise diary.
 ► Via weekly check- in with physiotherapist.
 ► Via reporting safety concerns and 
adverse events as per university policy.
Documentation of compliance
 ► Via exercise diary and weekly check- in.
Treatment effect


















  Cytokines Collection at the James Cook University 
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of change in aerobic activity across the duration of the 
study. Specifically, comparisons will be made on a week- 
by- week basis as to whether participants meet or exceed 
MS general and advanced aerobic exercise guidelines.
Acceptability of the FEPP
Participant survey
A participant survey will provide an initial assessment of 
the acceptability of the intervention to the participants. 
Three key areas (satisfaction, usability and suitability) will 
be explored in a short survey using a 5- point Likert scale 
(online supplementary file) based on similar surveys used 
with individuals with MS.38 51 The survey will be provided 
electronically to each participant on completion of the 
study via the survey platform Qualtrics.52 If participants 
are unable to access the survey electronically, it will be 
provided in paper format. Survey responses will remain 
anonymous.
Focus group interviews
Focus group interviews will take place during the 6- week 
postintervention period to gain greater insight into 
participants’ perceptions of the FEPP than the survey 
alone. Question design will be based on participant survey 
results regarding acceptability and recommendations for 
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Focus group Acceptability of intervention
 ► Participant survey results will guide the 
questions.
Effectiveness of the FEPP
 ► Changes in participation in physical activity, 
exercise or sport during the programme.
 ► Changes in energy levels during the 
programme.
 ► Changes in high- level mobility during the 
programme.
 ► Long- term changes in participation in physical 
activity, exercise or sport.
Goals
 ► Goal setting.
 ► Achievement /non- achievement of goals.
Finding the balance
Plans to continue with physical activity, exercise 
or sport
Suggestions to improve the FEPP or the process.
 ► Participant survey results will guide the 
questions.
will explore the participants’ perspectives on the effects 
of the programme. The focus group study will adopt an 
exploratory qualitative descriptive methodology in order 
to gain a rich description of participants’ experiences 
of the FEPP and to produce authentic reporting of the 
participants’ experience.53 54
All participants will be invited to attend the focus group 
interviews. Each group will contain a minimum of three 
and a maximum of six participants per group, depending 
on participant availability. Where participants are unable 
to attend a focus group interview, they will be offered a 
one- to- one interview.
Methods used to determine FEPP acceptability are 
outlined in table 4.
data management
On entry to the study, participants will be allocated a 
unique identifying code which will then be recorded 
on all datasets pertaining to that individual. The confi-
dential coding system will be held in a file separate from 
the other datasets. All data will be stored on the primary 
researcher’s computer, which is password protected. 
A secondary copy will be stored on a secure research 
storage platform. When in use, all data will be saved to 
the computer and backed up daily. On completion, data 
will be stored in the JCU institutional repository for a 
minimum of 15 years.
Patient and public involvement
A qualitative study on active participation in sport and 
exercise informed the development of this protocol.1 
Participants with minimal disability from MS highlighted 
that they want to participate in their preferred exercise 
or sport at a time that suits them. Importantly, partici-
pants identified that they need assistance in determining 
the dose of exercise they should undertake. This is the 
premise for the current feasibility study.
dAtA AnAlySIS
Data analysis will occur in accordance with the objectives 
of the study: to assess the feasibility of the FEPP for indi-
viduals with MS and to assess the feasibility of conducting 
a larger clinical trial.
Feasibility data analysis
Descriptive statistics will be used to report on the process, 
resources, management and scientific feasibility domains 
of this study. The process domain (eg, recruitment and 
retention) will inform the feasibility of achieving the 
sample size required for a larger trial. The resources 
and management domains will inform the financial and 
administrative requirements for a larger trial. The scien-
tific domain will identify the suitability of the outcome 
measures and any risk management required for a larger 
trial. In addition, the scientific domain will provide 
preliminary data on the effect and acceptability of the 
FEPP for individuals with MS and hence the feasibility of 
the FEPP.
Clinical data analysis
Clinical outcomes will be analysed descriptively rather 
than through formal hypothesis testing, as is the nature 
of feasibility trial data.55 Change from pre- FEPP to post- 
FEPP will be described based on the (1) GAS; (2) exercise 
frequency, intensity and duration of exercise; (3) Subjec-
tive Vitality Scale; (4) HiMAT; and (5) cytokine levels. 
Changes in cytokine levels will be analysed with conven-
tional flow cytometry analysis software by gating on the 
appropriate bead clusters and measuring the phyco-
erythrin median value for the bound analyte.
FEPP acceptability data analysis
Participant survey responses will be analysed descrip-
tively using frequency distribution, central tendency and 
dispersion. Focus group data will be analysed in accor-
dance with the exploratory qualitative descriptive meth-
odology. Following reading and rereading of the dataset, 
each line of data will be coded, using a short title or word 
enabling clear identification of topics within the data.56 
Inductive thematic analysis will be used to analyse the 
patterns, with similar codes brought together to identify 
emergent themes from the bottom up.54 57 Themes will 
subsequently be reviewed to check that they work in rela-
tion to the coded extracts by checking and rechecking 
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and a thematic map is created.57 Codes and patterns from 
one focus group dataset will be reviewed by a secondary 
researcher to check and verify, or to identify error, as part 
of quality assurance.58 In addition, member checking 
will take place with one member from each focus group 
to ensure appropriate representation of participant 
experiences.
Interpretation of the data through thematic analysis 
will enable a well- organised descriptive evaluation of the 
FEPP from the perspective of the participants. The final 
analysis will involve exploration of how the focus group 
data explain the quantitative participant survey data 
in accordance with the sequential explanatory mixed 
methods design.31
data analysis summary
Collectively, the data will provide a comprehensive 
analysis of the feasibility of conducting a larger trial to 
assess the effectiveness of using the FEPP with individ-
uals with MS. Progression to a larger trial will be depen-
dent on the logistics of implementing the trial (process 
and resource metrics), together with the feasibility of 
the FEPP. Feasibility of the FEPP will be dependent on 
participants’ safety, ability to modify exercise prescription 
with minimal supervision, preliminary effectiveness and 
participant acceptability with the intervention. Progres-
sion to a larger trial will be dependent on achievement of 
specified minimum success criteria.
Ethics and dissemination
Ethical approval has been obtained for this study protocol 
from the JCU Human Research Ethics Committee 
(H7956). The research team will be briefed on the 
requirements for conduct of this study in accordance with 
the National Statement on Ethical Conduct in Human 
Research.59
This novel approach to participation in exercise in sport 
has been guided and driven by individuals with MS who 
have minimal disability. This approach has the potential 
to empower individuals with MS to independently engage 
in and optimise their participation in exercise according 
to their own preferences. The results of this study will 
inform future research in finding the balance between 
too much and too little participation in exercise and 
sport, for people with MS. Dissemination of study find-
ings is planned via peer- reviewed journals, national and 
international conferences and associated media releases.
Contributors MS is the principal investigator. MS, GW and RB conceived and 
designed the study. MS wrote the first draft of the manuscript with subsequent 
revisions from all authors. MS will lead the operation of the study with support from 
GW and RB.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement No data are available. As this is a protocol paper 
there are currently no data.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId id
Moira Smith http:// orcid. org/ 0000- 0003- 2085- 7522
rEFErEnCES
 1 Smith M, Neibling B, Williams G, et al. A qualitative study of active 
participation in sport and exercise for individuals with multiple 
sclerosis. Physiother Res Int 2019;24:e1776.
 2 Smith M, Barker R, Williams G, et al. The effect of exercise on 
high- level mobility in individuals with neurodegenerative disease: a 
systematic literature review. Physiotherapy 2020;106:174–93.
 3 Kjølhede T, Vissing K, de Place L, et al. Neuromuscular adaptations 
to long- term progressive resistance training translates to improved 
functional capacity for people with multiple sclerosis and is 
maintained at follow- up. Mult Scler 2015;21:599–611.
 4 Latimer- Cheung AE, Pilutti LA, Hicks AL, et al. Effects of exercise 
training on fitness, mobility, fatigue, and health- related quality of life 
among adults with multiple sclerosis: a systematic review to inform 
Guideline development. Arch Phys Med Rehabil 2013;94:1800–28.
 5 Gunn H, Markevics S, Haas B, et al. Systematic review: the 
effectiveness of interventions to reduce falls and improve 
balance in adults with multiple sclerosis. Arch Phys Med Rehabil 
2015;96:1898–912.
 6 Learmonth YC, Ensari I, Motl RW. Physiotherapy and walking 
outcomes in adults with multiple sclerosis: systematic review and 
meta- analysis. Physical Therapy Reviews 2016;21:160–72.
 7 Pearson M, Dieberg G, Smart N. Exercise as a therapy for 
improvement of walking ability in adults with multiple sclerosis: a 
meta- analysis. Arch Phys Med Rehabil 2015;96:1339–48.
 8 Kim Y, Lai B, Mehta T, et al. Exercise training guidelines for multiple 
sclerosis, stroke, and Parkinson disease: rapid review and synthesis. 
Am J Phys Med Rehabil 2019;98:613–21.
 9 InAmerican College of Sports Medicine. ACSM's guidelines for 
exercise testing and prescription 10th. Philadelphia, Pennsylvania: 
Wolters Kluwer Health, 2018.
 10 Australian Government Department of Health. Australia’s physical 
activity and sedentary behaviour guidelines for adults (18-64 years), 
2019. Available: https://www. health. gov. au/ internet/ main/ publishing. 
nsf/ Content/ health- pubhlth- strateg- phys- act- guidelines2019
 11 Thomas S, Kersten P, Thomas PW, et al. Exploring strategies used 
following a group- based fatigue management programme for people 
with multiple sclerosis (facets) via the fatigue management strategies 
questionnaire (FMSQ). BMJ Open 2015;5:e008274.
 12 Michie S, Ashford S, Sniehotta FF, et al. A refined taxonomy of 
behaviour change techniques to help people change their physical 
activity and healthy eating behaviours: the CALO- RE taxonomy. 
Psychol Health 2011;26:1479–98.
 13 Klaren RE, Motl RW, Dlugonski D, et al. Objectively quantified 
physical activity in persons with multiple sclerosis. Arch Phys Med 
Rehabil 2013;94:2342–8.
 14 Latimer- Cheung AE, Martin Ginis KA, Hicks AL, et al. Development of 
evidence- informed physical activity guidelines for adults with multiple 
sclerosis. Arch Phys Med Rehabil 2013;94:1829–36.
 15 Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training 
on fitness and quality of life in multiple sclerosis. Ann Neurol 
1996;39:432–41.
 16 Pilutti LA, Greenlee TA, Motl RW, et al. Effects of exercise training 
on fatigue in multiple sclerosis: a meta- analysis. Psychosom Med 
2013;75:575–80.
 17 Blikman LJ, Huisstede BM, Kooijmans H, et al. Effectiveness 
of energy conservation treatment in reducing fatigue in multiple 
sclerosis: a systematic review and meta- analysis. Arch Phys Med 
Rehabil 2013;94:1360–76.
 18 Andreasen AK, Stenager E, Dalgas U. The effect of exercise therapy 
on fatigue in multiple sclerosis. Mult Scler 2011;17:1041–54.
 19 Platta ME, Ensari I, Motl RW, et al. Effect of exercise training on 
fitness in multiple sclerosis: a meta- analysis. Arch Phys Med Rehabil 
2016;97:1564–72.
 20 Paltamaa J, Sjögren T, Peurala SH, et al. Effects of physiotherapy 
interventions on balance in multiple sclerosis: a systematic review 

















pen: first published as 10.1136/bm





10 Smith M, et al. BMJ Open 2020;10:e035378. doi:10.1136/bmjopen-2019-035378
Open access 
 21 Kjølhede T, Vissing K, Dalgas U. Multiple sclerosis and progressive 
resistance training: a systematic review. Mult Scler 2012;18:1215–28.
 22 White LJ, Castellano V. Exercise and brain health--implications for 
multiple sclerosis: Part 1--neuronal growth factors. Sports Med 
2008;38:91–100.
 23 Kjølhede T, Siemonsen S, Wenzel D, et al. Can resistance training 
impact MRI outcomes in relapsing- remitting multiple sclerosis? Mult 
Scler 2018;24:1356–65.
 24 Briken S, Rosenkranz SC, Keminer O, et al. Effects of exercise 
on irisin, BDNF and IL-6 serum levels in patients with progressive 
multiple sclerosis. J Neuroimmunol 2016;299:53–8.
 25 Campos C, Rocha NBF, Lattari E, et al. Exercise- Induced 
neuroprotective effects on neurodegenerative diseases: the key role 
of trophic factors. Expert Rev Neurother 2016;16:723–34.
 26 Mokhtarzade M, Ranjbar R, Majdinasab N, et al. Effect of aerobic 
interval training on serum IL-10, TNFα, and adipokines levels in 
women with multiple sclerosis: possible relations with fatigue and 
quality of life. Endocrine 2017;57:262–71.
 27 Deckx N, Wens I, Nuyts AH, et al. 12 weeks of combined endurance 
and resistance training reduces innate markers of inflammation in a 
randomized controlled clinical trial in patients with multiple sclerosis. 
Mediators Inflamm 2016;2016:1–13.
 28 White LJ, Castellano V. Exercise and brain health--implications for 
multiple sclerosis: Part II--immune factors and stress hormones. 
Sports Med 2008;38:179–86.
 29 Negaresh R, Motl RW, Mokhtarzade M, et al. Effects of exercise 
training on cytokines and adipokines in multiple sclerosis: a 
systematic review. Mult Scler Relat Disord 2018;24:91–100.
 30 Kjølhede T, Dalgas U, Gade AB, et al. Acute and chronic cytokine 
responses to resistance exercise and training in people with multiple 
sclerosis. Scand J Med Sci Sports 2016;26:824–34.
 31 InCreswell JW, Plano Clark VL. Designing and conducting mixed 
methods research. Third ed. London;Thousand Oaks, California;New 
Delhi;Singapore: SAGE, 2018.
 32 Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple 
sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 
2018;17:162–73.
 33 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: 
an expanded disability status scale (EDSS). Neurology 
1983;33:1444–52.
 34 Lublin FD. New multiple sclerosis phenotypic classification. Eur 
Neurol 2014;72 Suppl 1:1–5.
 35 Julious SA. Sample size of 12 per group rule of thumb for a pilot 
study. Pharm Stat 2005;4:287–91.
 36 Bowling A. Just one question: if one question works, why ask 
several? J Epidemiol Community Health 2005;59:342–5.
 37 Learmonth YC, Motl RW. Important considerations for feasibility 
studies in physical activity research involving persons with multiple 
sclerosis: a scoping systematic review and case study. Pilot 
Feasibility Stud 2018;4:1.
 38 Learmonth YC, Adamson BC, Kinnett- Hopkins D, et al. Results of a 
feasibility randomised controlled study of the guidelines for exercise 
in multiple sclerosis project. Contemp Clin Trials 2017;54:84–97.
 39 Adamson BC, Learmonth YC, Kinnett- Hopkins D, et al. Feasibility 
study design and methods for project gems: guidelines for exercise 
in multiple sclerosis. Contemp Clin Trials 2016;47:32–9 https:// doi. 
org/
 40 World Health Organisation. International classification of functioning, 
disability and health (ICF), 2001. Available: www. who. int/ 
classifications/ icf/ en/ [Accessed 02.04.2019].
 41 Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method 
for evaluating comprehensive community mental health programs. 
Community Ment Health J 1968;4:443–53.
 42 Turner- Stokes L. Goal attainment scaling (gas) in rehabilitation: a 
practical guide. Clin Rehabil 2009;23:362–70.
 43 Khan F, Pallant JF, Turner- Stokes L. Use of goal attainment scaling in 
inpatient rehabilitation for persons with multiple sclerosis. Arch Phys 
Med Rehabil 2008;89:652–9.
 44 Bovend'Eerdt TJH, Botell RE, Wade DT. Writing smart rehabilitation 
goals and achieving goal attainment scaling: a practical guide. Clin 
Rehabil 2009;23:352–61.
 45 Kierkegaard M, Lundberg IE, Olsson T, et al. High- intensity resistance 
training in multiple sclerosis - An exploratory study of effects on 
immune markers in blood and cerebrospinal fluid, and on mood, 
fatigue, health- related quality of life, muscle strength, walking and 
cognition. J Neurol Sci 2016;362:251–7.
 46 Zhou X, Fragala MS, McElhaney JE, et al. Conceptual and 
methodological issues relevant to cytokine and inflammatory marker 
measurements in clinical research. Curr Opin Clin Nutr Metab Care 
2010;13:541–7.
 47 Bostic TJ, McGartland Rubio D, Hood M. A validation of the 
subjective vitality scale using structural equation modeling. Soc Indic 
Res 2000;52:313–24.
 48 Dawes H, Collett J, Meaney A, et al. Delayed recovery of leg fatigue 
symptoms following a maximal exercise session in people with 
multiple sclerosis. Neurorehabil Neural Repair 2014;28:139–48.
 49 Williams G, Morris ME, Greenwood BN, et al. The high- level mobility 
assessment tool for traumatic brain injury: user manual. Melbourne: 
La Trobe University, 2004.
 50 Williams GP, Greenwood KM, Robertson VJ, et al. High- Level 
mobility assessment tool (HiMAT): interrater reliability, retest reliability, 
and internal consistency. Phys Ther 2006;86:395–400.
 51 Aminian S, Motl RW, Rowley J, et al. Management of multiple 
sclerosis symptoms through reductions in sedentary behaviour: 
protocol for a feasibility study. BMJ Open 2019;9:e026622.
 52 Qualtrics XM. Qualtrics, 2019. Available: https://www. qualtrics. com/ 
au/ [Accessed 14.06.19 2019].
 53 Sandelowski M. What's in a name? qualitative description revisited. 
Res Nurs Health 2010;33:77–84.
 54 Stanley M. Qualitative descriptive a very good place to start. In: 
Nayer S, Stanley MD, eds. Qualitative research methodologies for 
occupational science and therapy. Oxon: Routledge, 2015.
 55 Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, 
why and how. BMC Med Res Methodol 2010;10:1.
 56 Saldana J. The coding manual for qualitative researchers. 2nd. 
London England: SAGE, 2013.
 57 Braun V, Clarke V. Using thematic analysis in psychology. Qual Res 
Psychol 2006;3:77–101.
 58 Braun V, Clarke V. Successful qualitative research a practical guide 
for beginners. London, England: SAGE Publications Ltd, 2013.
 59 National Health and Medical Research Council. National statement 
on ethical conduct in human research, 2018. Available: https://

















pen: first published as 10.1136/bm
jopen-2019-035378 on 18 M
arch 2020. D
ow
nloaded from
 
